The controversial outcomes of mTOR inhibitors in sepsis clinical trials highlights the extreme importance of the intervention timing and immune-metabolic stratification of patients-inhibiting mTOR during the immunosuppressive stage may further impair T-cell function and exacerbate the condition (56). The gene discussed is MTOR; the disease is Sepsis.